Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vepoloxamer - Savara Pharmaceuticals

Drug Profile

Vepoloxamer - Savara Pharmaceuticals

Alternative Names: ANX-188; CRL-5861; FLOCOR; MST-188; Poloxamer 188 NF; Purified 188; Purified poloxamer 188

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytRx Corporation
  • Developer Mast Therapeutics; Savara Pharmaceuticals
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Cell membrane structure modulators; Surface active agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders; Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myocardial infarction
  • No development reported Acute lung injury; Cancer; CNS disorders; Muscular dystrophies; Peripheral nervous system diseases; Stroke
  • Discontinued Chronic heart failure; Peripheral arterial occlusive disorders; Vaso-occlusive crisis

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for preclinical development in Stroke in USA (Parenteral)
  • 24 Jun 2018 Biomarkers information updated
  • 27 Apr 2017 Mast Therapeutics has merged with Savara Pharmaceuticals and will operate under the name Savara Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top